Latest Financial Health News

NZME Limited has upgraded its FY25 Operating EBITDA guidance, signaling stronger-than-expected financial performance despite economic headwinds. The company now expects earnings between $59 million and $62 million, up from its earlier forecast.

DMC Mining Limited reports steady progress on its Guinea projects’ licences amid ongoing ASX re-admission efforts, despite critically low cash reserves.

Klevo Rewards Limited reports a strong quarter with a tenfold increase in customer receipts and positive cash flow, completing a $3.4 million entitlement offer and advancing steps toward ASX reinstatement.

DMC Mining Group reported a modest cash outflow for the September quarter while securing a loan facility variation and initiating a $6 million capital raise to support its exploration ambitions.

Motio Limited has raised $1.73 million through a placement to accelerate its digital display network expansion and repay debt early, aiming to reach profitability sooner.

Pro-Pac Packaging has entered voluntary administration, securing relief to defer its financial reporting and annual general meeting obligations for up to two years. This move pauses key corporate governance duties as the company navigates its restructuring.

Atomos Limited has posted its first positive EBITDA quarter since late 2022, driven by strong sales of its flagship Ninja and Shinobi products. The company’s operational overhaul and strategic product launches set the stage for continued growth into Q2 FY26.

Optiscan Imaging Ltd secured $17.75 million in a fully underwritten equity raise, fueling clinical studies and regulatory preparations for its innovative medical imaging devices. The company also reported progress in international trials and strengthened its cash position to nearly $20 million.

Starpharma has secured two major partnership agreements with Genentech and Radiopharm Theranostics, unlocking significant upfront payments and milestone potential while advancing its clinical pipeline.

XPON Technologies reports a robust Q1 FY26 with 17.5% revenue growth, positive cash flow, and strategic leadership changes, setting a strong foundation for the year ahead.

Syntara Limited reports encouraging Phase 2a results for amsulostat in myelofibrosis, with significant symptom relief and spleen volume reduction sustained over 12 months, alongside new clinical trial initiations and a solid cash position.

Coronado Global Resources has proposed a significant financial support transaction with Stanwell Corporation, aiming to enhance liquidity, extend coal supply agreements, and support Queensland’s energy needs and local employment.